The Institute for Clinical and Economic Review’s (ICER) new Patient Engagement Program is a big leap forward for the drug pricing watchdog’s efforts to include the patient perspective in each stage of its cost-effectiveness assessments, ICER Founder and President Steven Pearson writes in a blog post published on The Donaghue Foundation.
Prior to launching a new value assessment, ICER will reach out to “disease-specific patient groups” to outline the assessment process and “promote conversations and connections with other patient leaders,” Pearson writes.
“Weighing evidence, uncertainty, hope, need, and money must be something we bring out of corporate backrooms and into the light of public deliberation,” he writes. “And there it is that the patient voice must be the first to be heard.”
To read the full blog post, click here.
